ClinicalTrials.gg
TerminatedNCT01559103Updated Feb 9, 2021

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

A Phase 1 interventional study of MEDI5117 and MEDI5117 Placebo in Rheumatoid Arthritis, sponsored by Novo Nordisk A/S. Terminated at 3 sites in 3 countries. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-09.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Arthritis, Rheumatoid by Novo Nordisk A/S — none open to participants now, none under way, none of them phase 3. Arthritis, Rheumatoid · Novo Nordisk A/S.

Enrollment
7th of 14
39 · median 38
Started
2012
with 5 others
Phase 1
8 of 14
none open now
Registered
6th of 14
by date

Among the 14 studies in Arthritis, Rheumatoid by Novo Nordisk A/S, this one is the 7th largest by enrollment, is one of 6 that started in 2012, is one of 8 in phase 1, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 14 studies in Arthritis, Rheumatoid by Novo Nordisk A/S is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Arthritis, Rheumatoid by Novo Nordisk A/S as a file.
02

Study summary

Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients

Read the detailed description

A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI5117 (anti-IL-6)

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Phase I
  • Biologic
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active Rheumatoid Arthritis (RA) for 6 months or more.
  • Males or nonpregnant, nonlactating femails aged 20 to 75 years, inclusive.
  • (BMI) between 19 and 36 kg/m2 and weight between 50 and 145 kg, inclusive.
  • Males, unless surgically sterile, must use 2 effective methods of from Day 1 through follow-up.

Exclusion criteria

Exclusion Criteria:

  • History or presence of any disease or disorder which has not been stable over the previous 3 months.
  • History of liver disease, elevations, or Gilbert's Syndrome.
  • Any systematic inflammatory condition in addition to RA (polymyalgia rheumatica, giant cell arthritis, systemic lupus, gout, pyrophosphate arthropathy).
  • Current, chronic pain disorders including fibromyalgia and chronic regional pain syndromes or chronic fatigue syndromes.
  • Intramuscular injection or intraarticular steroid injection within 1 month of enrollment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    MEDI5117

    Intravenous infusion administered over 60 minutes

    Biological: MEDI5117

  • Placebo comparator
    MEDI5117 Placebo

    Intravenous infusion administered over 60 minutes

    Biological: MEDI5117 Placebo

Interventions

  • BiologicalMEDI5117

    Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg

  • BiologicalMEDI5117 Placebo

    Intravenous infusion administered over 60 minutes

06

What researchers measure

Primary outcomes

  1. Description of the safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram), physical examination, and safety laboratory variables.

    Time frame: From Baseline up to 64 weeks

Secondary outcomes

  1. Description of pharmacokinetics in terms of Maximum serum concentration (Cmax), time to Cmax (tmax), terminal rate constant(λz), terminal half-life (t1/2 λz).

    Time frame: From Day 1 Predose, 2h, 12h, 24h, day 7, week 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56 and week 64.

  2. Description of pharmacokinetics in terms of area under the serum concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-t)] and from zero to infinity (AUC).

    Time frame: From Day 1 Predose, 2h, 12h, 24h, day 7, week 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56 and week 64.

  3. Description of pharmacokinetics in terms of area under the serum concentration-time curve from zero to the time of concentration at Weeks 6 and 12 [AUC(0-6w) and AUC(0 12w)].

    Time frame: From Day 1 Predose, 2h, 12h, 24h, day 7, week 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56 and week 64.

  4. Descriptions of pharmacokinetics in terms of systemic clearance (CL), volume of distribution during terminal phase (Vz), and volume of distribution at steady state (Vdss).

    Time frame: From Day 1 Predose, 2h, 12h, 24h, day 7, week 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56 and week 64.

  5. Description of pharmacodynamics in terms of total interleukin 6 (IL-6) and free IL-6 (exploratory) in plasma and high sensitive C-reactive protein (hs-CRP) pre and post MEDI5117 or placebo administration and their corresponding change from baseline.

    Time frame: From Baseline day -1 to week 64

  6. Description of immunogenicity in terms of positive or negative for the presence of antidrug antibodies against MEDI5117 in blood.

    Time frame: From Baseline day -1 to week 64

07

Study locations

3 sites
  • Novo Nordisk Investigational Site
    Overland Park, Kansas, United States
  • Novo Nordisk Investigational Site
    Berlin, Germany
  • Novo Nordisk Investigational Site
    Belfast, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2012 to primary completion in Feb 2014, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2012
First posted
Mar 21, 2012
StartActual
May 31, 2012
Primary completionActual
Feb 28, 2014
CompletionActual
Feb 28, 2014
Last update
Feb 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01559103
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 21, 2012
Start date
May 31, 2012
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014
Last update
Feb 9, 2021

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion